UC, Berkeley files brief in CRISPR Federal Circuit case
The University of California (UC), Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 August 2017 Gene-editing company CRISPR Therapeutics has partnered with the cancer centre at Massachusetts General Hospital to develop T cell therapies for treating the disease.
15 November 2017 Excision BioTherapeutics has become the first company to secure exclusive licences from the University of California, Berkeley for “newly discovered” CRISPR gene editors.
23 August 2017 Gene-editing company CRISPR Therapeutics has partnered with the cancer centre at Massachusetts General Hospital to develop T cell therapies for treating the disease.
15 November 2017 Excision BioTherapeutics has become the first company to secure exclusive licences from the University of California, Berkeley for “newly discovered” CRISPR gene editors.
23 August 2017 Gene-editing company CRISPR Therapeutics has partnered with the cancer centre at Massachusetts General Hospital to develop T cell therapies for treating the disease.
15 November 2017 Excision BioTherapeutics has become the first company to secure exclusive licences from the University of California, Berkeley for “newly discovered” CRISPR gene editors.